SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BMcV who wrote (2789)5/17/1999 10:07:00 AM
From: Biomaven  Read Replies (1) of 10280
 
Here's my quick take on the nori releases and the CC:

1. They showed the drug is comparable to Claritin, but with faster onset (20 minutes vs. 160 minutes). The studies were not powered to show overall superiority over Claritin, and they didn't. Trials were multi-arm (different doses), which reduces power. No toxicity issues were revealed. One of the two week trials didn't quite reach significance at end of trial, because of growing placebo effect. (On the CC, they said Claritin was approved with 5 day trials). They were confident they would get once-a-day dosing.

2. They plan on spending around $25m on trials both this year and next, so the impact of J&J not paying half is not substantial.

3. J&J royalty appears to be single digits - 6% "wasn't far off."

4. They will obviously explore partnering (Glaxo came up several times, but they said there are 3-4 others). If they don't partner, they will just go for a bigger stake in a much smaller pie - won't try to compete w/ mass marketing etc.

5. Seemed fairly upbeat, but a little shaken, which is understandable given they only found out about this on Friday.

6. Maris was on the call - asked a reasonable question and was answered without any cursing that I could hear. <g>.

I bought a little more this morning.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News